Update
$Abeona Therapeutics (ABEO.US)$ Abeona Therapeutics: Beacon to Have Right to Evaluate, for 12-Month Period, Aav204 Capsid for Potential Use in Certain Ophthalmology Indications
Abeona Therapeutics: To Get Upfront Payment Upon Beacon's Exercise of Option to License Aav204, With Extra Payments on Achievement of Milestones
Abeona Therapeutics: To Get Upfront Payment Upon Beacon's Exercise of Option to License Aav204, With Extra Payments on Achievement of Milestones
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
